Benitec Biopharma Inc(BNTC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.09 | Insider Own | 2.51% | Shs Outstand | 34.4M | Perf Week | 1.04% |
| Market Cap | 0.30B | Forward P/E | - | EPS next Y | -20% | Insider Trans | - | Shs Float | 34.0M | Perf Month | -8.77% |
| Enterprise Value | 0.13B | PEG | - | EPS next Q | -0.28 | Inst Own | 99.24% | Short Float | 5.86% | Perf Quarter | -28.07% |
| Income | -0.05B | P/S | - | EPS this Y | -26.28% | Inst Trans | 2.17% | Short Ratio | 11.38 | Perf Half Y | -26.86% |
| Sales | 0.00B | P/B | 1.7 | EPS next 5Y | -11.27% | ROA | -32.28% | Short Interest | 1.99M | Perf YTD | -35.12% |
| Book/sh | 5.14 | P/C | 1.69 | EPS past 3/5Y | 58.92% 55.32% | ROE | -33.21% | 52W High | -47.6% ($16.68) | Perf Year | -45.95% |
| Cash/sh | 5.16 | P/FCF | - | Sales past 3/5Y | - | ROIC | -25.69% | 52W Low | 10.84% ($7.89) | Perf 3Y | 146.2% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 14.04% | Gross Margin | - | Volatility(W/M) | 6.04% 7.44% | Perf 5Y | -85.95% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.62 | Perf 10Y | -97.83% |
| Dividend Ex-Date | - | Quick Ratio | 34 | EPS Q/Q | -74.01% | Profit Margin | - | RSI (14) | 42.57 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 34 | Sales Q/Q | - | SMA20 | 0.22% ($8.72) | Beta | 0.24 | Target Price | $23.29 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/9/14 | SMA50 | -15.88% ($10.39) | Rel Volume | 0.77 | Prev Close | $8.83 |
| Employees | 24 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -1.21% - | SMA200 | -24.26% ($11.54) | Avg Volume(3M) | 0.17M | Price | $8.74 |
| IPO | 2014/6/23 | Option/Short | Yes/Yes | Trades | 2222 | Volume | 135,494 | Change | -1.02% |
🧬 Benitec Biopharma (BNTC) is a clinical-stage biotech company developing treatments for rare neuromuscular diseases using its proprietary gene therapy platform, which combines gene silencing with normal gene replacement. Headquartered in the US, the company operates its pipeline around its lead candidate targeting oculopharyngeal muscular dystrophy.
Over the past 1 year, on the lower side
48% below its 1-year high.
Traded less than usual. That is 77% of its average volume.
BNTC has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -26.3% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -86.0%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 99.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #264 of 597 in the industry
Based on market cap of $305M.
AGEN#262 Agenus Inc $309M PER 2.6 
IRD#263 Opus Genetics Inc $305M PER - BNTC#264 Benitec Biopharma Inc $305M PER - 
SABS#265 SAB Biotherapeutics Inc $305M PER - 
VOGX#266 Vogenx Inc $301M PER - 
FAQ
What kind of company is BNTC?
BNTC belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BNTC?
The market cap of BNTC is approximately $305M, ranking 3,622 within its sector.
What is the 52-week high and low for BNTC?
BNTC has recorded a 52-week high of $16.68 and a low of $7.89.
